News Releases

ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.

ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for

ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub being held at the Bellagio Resort & Casino in Las

ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in  JAMA Network Open  titled, “Transcutaneous Electrical Nerve Stimulation and Pain With

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles,

First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT

ROCKAWAY, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that TAC-STIM™, its non-invasive vagus nerve stimulation (nVNS) product for human performance, has been named a national semifinalist

ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6,

ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers Investor Summit at the historic Bank of New York.

ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced its participation in  Hacking the Vagus Nerve, a documentary from the Healing Journeys series produced by The Root Cause Project and

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026.

ROCKAWAY, N.J., April 7, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve

ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience  titled “Adjunctive non-invasive vagus nerve stimulation for

ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company’s VP, Sales, and Michael Fox will

electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and

Record f ull year 2025 net sales of $ 32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to

ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference   March 22-24 at the Ritz-Carlton in Laguna Niguel, California.

ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market

ROCKAWAY, N.J. , Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™

Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025  Revenue growth of approximately 26% over full-year 2024 Cash, cash equivalents, and marketable securities (“Total Cash”) balance of